Table 3.
LAG-3 expression on tumor-associated immune cells and study observations related to expression.
| Reference | Lymphocyte Subset | Types of Cells | Expression of Other Molecules | Observations |
|---|---|---|---|---|
| [83] | TALs | ND | FOXP-3, CD8 | assessment of LAG-3+ lymphocytes, association with PD-L1 expression and BRCA status |
| [84] | TALs | CD8+ T cells | PD-1, CTLA-4 (murine); PD-1, TIM-3 (human) | expression assessment, assessment of immune checkpoint inhibition |
| TALs | CD4+ T cells | PD-1, CTLA-4 (murine); PD-1, TIM-3 (human) | ||
| [85] | TILs | CD8+ T cells | PD-1 | expression assessment, assessment of the enhancement of anti-tumor immunity and immune checkpoint inhibition |
| TILs | CD4+ T cells | PD-1 | ||
| [86] | TILs | CD8+ T cells | PD-1 | expression assessment, comparative assessment of cells function, assessment of immune checkpoint inhibition, indication that PD-1 and LAG-3 can be induced by ascites without antigenic stimulation |
| TALs | CD8+ T cells | PD-1 | ||
| PBLs | CD8+ T cells | PD-1 | ||
| [11] | TILs | CD8+ T cells | PD-1, TIM-3, CTLA-4 | expression assessment, correlations between subsets, determination of clinical relevance and risk factors |
| TILs | CD4+ T cells | PD-1, TIM-3, CTLA-4 | ||
| TALs | CD8+ T cells | PD-1, TIM-3, CTLA-4 | ||
| TALs | CD4+ T cells | PD-1, TIM-3, CTLA-4 | ||
| PBLs | CD8+ T cells | PD-1, TIM-3, CTLA-4 | ||
| PBLs | CD4+ T cells | PD-1, TIM-3, CTLA-4 | ||
| [26] | TILs | CD8+ T cells | PD-1, PD-L1, CTLA-4, TIM-3 | expression assessment, correlations between subsets, survival prediction |
| [87] | TILs | ND | PD-1, PD-L1, ICOS | expression assessment, survival prediction |
| [88] | TILs | ND | PD-1, PD-L1, TIM-3 | expression assessment |
| [89] | TILs | PD-1+CD103+CD8+ T cells | TIM-3, CTLA-4 | expression assessment |
| [40] | MALs | CD8+ T cells | PD-1, TIM-3, BTLA | expression assessment |
| MALs | CD4+ T cells | PD-1, TIM-3, BTLA | ||
| [35] | PBMCs | CD8+ T cells | CTLA-4, TIGIT, TIM-3, PD-1 | immune checkpoints regulation via CCL23 |
| [37] | immune cells (not specified) | ND | IDO, TIM-3, PD-L1 | expression assessment, correlation with TILs, prognostic impact |
| [90] | ND | ND | CD274, VTCN1, CD47 | expression assessment |
| [91] | tumor-infiltrating immune cells | ND | PTPRCAP, CCL5, IFI16, IL15RA, GBP1 | expression assessment, association with DNA damage repair deficiency |
| [92] | ND | ND | MT1B, LRRC63, CA1, CDC25A | expression assessment, survival prediction |
| [93] | tumor- and stroma-infiltrating lymphocytes | CD8+ T cells | PD-1, GITR | expression assessment associated with chemotherapy |
| tumor- and stroma-infiltrating lymphocytes | FOXP3+ T cells | PD-1, GITR | ||
| [20] | ND | ND | PD-1, CTLA-4, TIM-3 | expression assessment, correlations with immune cells subsets, survival prediction |
| [94] | ND | ND | CTLA-4, ICOS, PD-1, PD-L1, TNFRSF18 | expression assessment, correlations with immune cells subsets, survival prediction |
TALs—tumor-associated lymphocytes, TILs—tumor-infiltrating lymphocytes, PBLs—peripheral blood lymphocytes, MALs—malignant ascites lymphocytes, PBMCs—peripheral blood mononuclear cells, TME—tumor microenvironment, ND—no data.